PLAU, plasminogen activator, urokinase, 5328

N. diseases: 439; N. variants: 8
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025202
Disease: melanoma
melanoma
0.040 AlteredExpression disease BEFREE We have targeted the urokinase-type plasminogen activator receptor (uPAR) with phosphorothioate antisense oligonucleotides (aODN) in vitro to evaluate the anti-invasive and anti-proliferative effects of uPAR down-regulation, as well as in vivo to evaluate anti-tumor and anti-metastatic activity. aODN-dependent uPAR downregulation in vitro was induced in cells of human melanoma, mammary carcinoma, ovarian carcinoma and SV-40-transformed embryonic lung fibroblasts. uPAR was determined by an antibody-based assay and by semiquantitative polymerase chain reaction. 15054877 2004
CUI: C0025202
Disease: melanoma
melanoma
0.040 AlteredExpression disease LHGDN The uPA concentrations positively correlated with those of PAI-1 measured in melanomas (r=0.45, p<0.01). 12684636 2003
CUI: C0025202
Disease: melanoma
melanoma
0.040 Biomarker disease BEFREE Tissue-type PA was present in endothelial cells in all lesions, whereas in metastases it could be detected in tumor cells in a minority of the lesions. u-PA, its receptor, PAI-1, and PAI-2 could not be detected in benign and in early stages but appeared frequently in advanced primary melanoma and melanoma metastasis lesions. u-PA was detected in stromal cells and in tumor cells at the invasive front, the u-PA receptor and PAI-2 in tumor cells, and PAI-1 in the extracellular matrix surrounding tumor cells. 8291613 1994
CUI: C0025202
Disease: melanoma
melanoma
0.040 Biomarker disease BEFREE These findings suggest a role for u-PA and PAI-1 in a relatively early stage of melanoma metastasis. 1918136 1991